Clinical trial NCT05679024: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Official title: Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Chronic Kidney Diseases
Atrial Fibrillation
Stroke
Intracerebral Hemorrhage
Major Bleed
Cardiovascular Complication
Death
Kidney Transplant; Complications
Thromboses, Venous
Keywords: Chronic kidney disease
Hemodialysis
Peritoneal dialysis
Kidney transplantation
Atrial fibrillation
Oral anticoagulation
Lead sponsor: Region Stockholm
Sponsor class: OTHER_GOV
First posted: 2023-01-10
Enrollment: 1400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Pragmatic Prospective Open Label Parallel-Group Multicenter Phase 3b Randomized Controlled Clinical Trial
Primary purpose: TREATMENT

Brief summary: Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment. The study hypothesis is that compared to no anticoagulation, apixaban reduces the incidence of ischemic stroke without causing an unacceptable increase in fatal or intracranial bleeding events.

The secondary objectives are to evaluate the risk of all-cause mortality, cardiovascular events, and major bleeding in people with CKD stage 5 and AF treated with apixaban compared to standard of care without anticoagulation.

Trial design: Pragmatic Prospective Open Label Randomized Controlled Clinical Trial, phase 3b over 12-72 months.

Trial population: 1000-1400 patients at ≈50 sites in Sweden, Finland, Norway, Iceland and Poland Eligibility criteria: Adults ≥18 years with CKD stage 5 (ongoing treatment with any chronic dialysis treatment OR an estimated glomerular filtration rate (eGFR)\* \<20 ml/min/1.73 m2 at least twice 3 months apart of which at least one occasion is \<15 ml/min/1.73 m2 due to CKD during the last 12 months) and a diagnosis of chronic, paroxysmal, persistent, or permanent AF or atrial flutter (AFL) with CHA2DS2-VASc score ≥2 for men or ≥3 or more for women as an indication for oral anticoagulation.

The exclusion criteria are AF or AFL due to reversible causes, rheumatic mitral stenosis or moderate-to-severe non-rheumatic mitral stenosis at the time of inclusion into the study, a condition other than AF or AFL that requires chronic anticoagulation, contraindications for anticoagulation, active bleeding or serious bleeding within 3 months, planned for surgery within 3 months, and current use of strong inhibitors of both CYP3A4 and P-glycoprotein.

Interventions: Randomization 1:1 to treatment with apixaban 2.5 mg twice daily and standard of care, or standard of care and no anticoagulation.

Outcome measures: primary efficacy (time to first ischemic stroke); primary safety (the composite of time to first intracranial bleeding or fatal bleeding); secondary efficacy (time to all-cause mortality, time to cardiovascular event or cardiovascular death); secondary safety (time to first major bleeding according to International Society on Thrombosis and Hemostasis (ISTH) criteria)

Detailed description: Background and rationale: Atrial fibrillation (AF) is common (15-30%) in patients with chronic kidney disease (CKD) and AF prevalence increases with severity of CKD. In late stages of CKD, randomized control trials (RCT) of both efficacy and safety of any anticoagulation therapy, both warfarin and direct oral anticoagulation (DOAC) drugs, for stroke prophylaxis in AF are lacking. The efficacy of warfarin and DOACs have been evaluated in observational trials in patients with stage 5 CKD, but the results have been conflicting, and these studies were all subjected to selection bias in one way or the other. Instead, observational studies have demonstrated several adverse side-effects. Among them an increased number of bleedings including hemorrhagic stroke in patients treated with warfarin, and calciphylaxis, a very serious complications unknown in the normal population linked to the withdrawal of vitamin-K-dependent protection of vascular calcification in CKD. With apixaban treatment several benefits were reported. Firstly, a potential protective effect against ischemic stroke. Secondly, a lower incidence of bleeding complications as observed in the major trials, and thirdly, no disturbance in vitamin K turnover as compared to warfarin treatment. In addition, apixaban treatment does not require routine monitoring and have fewer drug/food interactions. For patients with CKD stage 5, treatment with apixaban appears to have a lower bleeding risk than warfarin treatment.

Rationale to study design: There are no previous randomized controlled clinical trials in this study population. The SACK study is conducted in approximately 50 sites in Sweden, Finland, Norway, Iceland and Poland, and additional European countries, if necessary. In Sweden, the study will be register-randomized (via the national Swedish Renal Register \[SNR\]) whereas the other countries in the study will include patients in a traditional way for clinical trials.

The study design will be an individually randomized two-armed parallel-group design. Apixaban will be prescribed and renewed by the local investigator via regular prescription or distributed by the investigating site at regular intervals in all participating countries. Due to open-label prescription and safety reasons, the study will be conducted as an open-label trial with end-point evaluation. Patients who are randomized to apixaban and those who are randomized to standard of care with no anti-coagulation will receive all other guideline-recommended standard of care treatments. Patients already on prior warfarin or apixaban therapy, or on regular low molecular weight heparin (LMWH) can also be randomized to either treatment arm (their current anticoagulation is discontinued at the inclusion visit) after an individualized risk assessment. At inclusion, patients will provide routine blood samples including hemoglobin, eGFR, and coagulation parameters.

The end of the clinical study for each individual patient is defined as the End of Study (EoS) visit. The EoS for a patient is after 72 months or when 247 primary events have been reached, whichever comes first. An interim analysis will take place after 1000 patient-years with the purpose to evaluate event rate and to be able to closer determine the exact number of patients and duration of the trial. The end of the clinical trial is defined as the last visit of the last subject in the study (LVLS).

A Data and Safety Monitoring Board (DSMB) will supervise this study, and primary safety and efficacy endpoints and major bleedings will additionally be evaluated by independent external reviewers according to a predefined Central Event Adjudication charter.

Exploratory outcomes: Time to first thromboembolic event defined as a composite of deep vein thrombosis, pulmonary embolism, transient ischemic attack Time to dialysis access thrombosis Time to kidney replacement therapy Delayed graft function in patients undergoing kidney transplantation Thrombosis of renal artery or vein in patients undergoing kidney transplantation

Among the secondary safety outcomes are time to major bleeding according to ISTH criteria. We are especially interested in the safety outcomes of the subgroup undergoing a kidney transplantation from the waiting list and therefore we have an extended protocol for those participants.

Eligibility criteria: Inclusion Criteria:

1. Signed Written Informed Consent
2. 18 years of age or older
3. Ongoing treatment with any chronic dialysis treatment OR an estimated glomerular filtration rate (eGFR)\* \<20 ml/min/1.73 m2 at least twice 3 months apart of which at least one occasion is \<15 ml/min/1.73 m2 due to CKD during the last year (12 months).
4. Diagnosis of chronic (i.e., repeated) paroxysmal, persistent, or permanent atrial fibrillation (AF) or atrial flutter (AFL)
5. CHA2DS2-VASc score ≥2 or more for men ≥3 or more for women as an indication for oral anticoagulation
6. Women of childbearing potential (WOCBP) should have a negative highly effective pregnancy test at screening and must agree to follow instructions for method(s) of contraception for the duration of treatment

Exclusion Criteria:

Participants may not be included in the study if any of the following criteria are met:

1. AF or AFL due to reversible causes (e.g., thyrotoxicosis, pericarditis)
2. Any degree of rheumatic mitral stenosis or moderate-to-severe non-rheumatic mitral stenosis at the time of inclusion into the study
3. Any condition other than AF or AFL that requires chronic anticoagulation (e.g., a prosthetic mechanical heart valve, antiphospholipid syndrome).
4. Any contraindication for anticoagulation including

   1. endocarditis
   2. documented intolerance for apixaban
   3. liver disease with documented coagulation disorder
   4. pregnancy or breast feeding
5. Active bleeding or serious bleeding within 3 months, or

   1. documented hemorrhagic blood dyscrasia
   2. patients currently receiving dual antiplatelet therapy
6. Planned for surgery

   1. kidney transplantation with a living donor within 3 months
   2. active on the kidney transplant waiting list at a kidney transplant center where apixaban use is prohibited
   3. valvular heart disease surgery
7. Current use of strong inhibitors of both CYP3A4 and P-glycoprotein in accordance with the summary of product characteristics (SmPC) of apixaban or regular intake of non-steroidal anti-inflammatory drugs (NSAID) or cyclooxygenase-2 (COX2) inhibitors
8. Any condition or circumstance in which the patient should not participate in the study according to the study investigator (reason documented in the pre-screening protocol)

Being active on the kidney transplant waiting list is not an exclusion criterion if it is allowed according to the current clinical guidelines at the transplant clinic where the patient is registered. The patient must report changes in waiting list status to the investigator promptly.

Primary outcomes:
measure: Ischemic stroke or systemic embolism (efficacy)
timeFrame: Up to 72 months
measure: Intracranial bleeding (including hemorrhagic stroke) and fatal bleeding (safety)
timeFrame: Up to 72 months
Secondary outcomes:
measure: All-cause mortality
timeFrame: Up to 72 months
measure: Cardiovascular event
timeFrame: Up to 72 months
measure: Individual components of cardiovascular event
timeFrame: Up to 72 months
measure: Major bleeding
timeFrame: Up to 72 months
measure: Major bleeding in patients undergoing kidney transplantation
timeFrame: Up to 72 months
Other outcomes:
measure: Thromboembolic event
timeFrame: Up to 72 months
measure: Dialysis access thrombosis
timeFrame: Up to 72 months
measure: Kidney replacement therapy initiation
timeFrame: Up to 72 months
Locations:
city: Helsinki
country: Finland
facility: Helsingfors University hospital
city: Tampere
country: Finland
facility: Tampere hospital
city: Turku
country: Finland
facility: Turku hospital
city: Reykjavík
country: Iceland
facility: Landspitali, the National University hospital of Iceland
city: Oslo
country: Norway
facility: Oslo Akershus
city: Oslo
country: Norway
facility: Oslo Universitetssjukhus Ullevål
city: Stavanger
country: Norway
facility: Stavanger hospital
city: Tromsø
country: Norway
facility: Tromsö hospital
city: Tønsberg
country: Norway
facility: Vestfold hospital
city: Falun
country: Sweden
facility: Falun hospital
state: Dalarna
city: Östersund
country: Sweden
facility: Östersund hospital
state: Jämtland
city: Falun
country: Sweden
facility: Lasarettet i Falun
state: Region Dalarna
city: Mora
country: Sweden
facility: Mora sjukhus
state: Region Dalarna
city: Kalmar
country: Sweden
facility: Länssjukhuset Kalmar
state: Region Kalmar Län
city: Kalix
country: Sweden
facility: Kalix hospital
state: Region Norrbotten
city: Lund
country: Sweden
facility: Skånes University hospital Lund
state: Region Skåne
city: Malmö
country: Sweden
facility: Skånes University hospital Malmö
state: Region Skåne
city: Umeå
country: Sweden
facility: Norrland University hospital Umeå
state: Region Västerbotten
city: Sundsvall
country: Sweden
facility: Sundsvall
state: Region Västernorrland
city: Västerås
country: Sweden
facility: Västmanlands sjukhus Västerås
state: Region Västmanland
city: Borås
country: Sweden
facility: Borås sjukhus
state: Region Västra Götaland
city: Gothenburg
country: Sweden
facility: Sahlgrenska University hospital
state: Region Västra Götaland
city: Skövde
country: Sweden
facility: Skaraborg hospital Skövde
state: Region Västra Götaland
city: Örebro
country: Sweden
facility: University hospital Örebro
state: Region Örebro Län
city: Linköping
country: Sweden
facility: Linköping University hospital
state: Region Östergötland
city: Jönköping
country: Sweden
facility: Länssjukhuset Ryhov
city: Karlshamn
country: Sweden
facility: Karlshamns sjukhus
city: Karlstad
country: Sweden
facility: Karlstad Central hospital
city: Norrköping
country: Sweden
facility: Norrköpings sjukhus
city: Skellefteå
country: Sweden
facility: Skellefteå hospital
city: Stockholm
country: Sweden
facility: Karolinska Universitetssjukhuset
city: Stockholm
country: Sweden
facility: Danderyd sjukhus AB
city: Uppsala
country: Sweden
facility: Akdemiska sjukhuset Uppsala
city: Varberg
country: Sweden
facility: Varberg hospital
Study officials:
affiliation: Karolinska University Hospital
name: Marie Evans, Ass Prof
role: PRINCIPAL_INVESTIGATOR
affiliation: Uppsala University
name: Maria Svensson, Prof
role: STUDY_CHAIR
References: